(2017). An immunogenic personalneoantigen vaccine for patients with melanoma. Nature 547, 217–221. https://doi. org/10.1038/nature22991 .https://www.ncbi.nlm.nih.gov/pubmed/28678778 . Ott, P.A., Hu-Lieskovan, S., Chmielowski, B., Govindan, R., Naing, A., Bhardwaj, N., Margolin, K., Awad, M.M., Hellmann, M.D., Lin, J.J., et al.(2020). A phase ib trial of personalized neoantigen therapy plus anti-PD-1 inpatients with advanced melanoma, non-small cell lung cancer, or bladder can-cer. Cell 183, 347–362.e24.